Callio Therapeutics
PrivateLast Round
Series A
Mar 3, 2025
Total Funding Raised
$187M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Callio Therapeutics operates in Healthcare & Life Sciences and is based in Seattle, Washington. Its latest recorded funding round was a Series A round in March 2025.
Callio Therapeutics is a biotechnology company that develops next-generation, multi-payload antibody-drug conjugates (ADCs) for cancer therapy.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Callio Therapeutics Comparables
Compare Callio Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Canwell Biotech Ltd. | 86% | |
| Eli Lilly and Company | 83% | |
| NetTargets | 78% |
For institutional investors. Book with your work email.
Callio Therapeutics Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Callio Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Omega Funds | Series A |
| SEEDS Capital | Series A |
| ClavystBio | Series A |
| EDBI | Series A |
| Norwest Venture Partners | Series A |
| Frazier Life Sciences | Series A |
| Novo Holdings | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 13, 2026
Monthly visitors increased 43% MoM.
- Aug 25, 2026
Grew 16% QoQ, from 19 to 22 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- recognized_asOct 15, 2026
Callio Therapeutics, Inc. wins Best New ADC Drug Developer at the 13th World ADC Awards, presented at the World ADC Awards Gala during World ADC San Diego 2026 in California on Oct 14th '26.
- hiresSep 10, 2026
Callio Therapeutics, Inc. appoints Zachary Hornby as Chief Executive Officer on Sep 9th '26 in California, Washington, and Singapore, as he leads the clinical-stage biotechnology company’s growth and advances its dual-payload ADC programs through clinical development.
- is_developingSep 9, 2026
Callio Therapeutics, Inc. is a clinical-stage biotechnology company developing dual-payload antibody-drug conjugates as targeted cancer therapies for high incidence tumors where better therapies are needed.
For institutional investors. Book with your work email.
Callio Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Callio Therapeutics's valuation, stock price, and market status.
Is Callio Therapeutics a public or private company?
Callio Therapeutics is a private company.
What is the current stock price of Callio Therapeutics?
Callio Therapeutics is a private company, so its shares have no public market price. Caplight tracks Callio Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Callio Therapeutics worth (valuation)?
Valuation information for Callio Therapeutics is not publicly available.
Can I buy Callio Therapeutics stock?
Callio Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Callio Therapeutics's last funding round?
Callio Therapeutics's most recent funding round was Series A on March 3, 2025.
Who are the main investors in Callio Therapeutics?
Key investors in Callio Therapeutics include Frazier Life Sciences.
Will Callio Therapeutics IPO soon?
No public IPO plans have been announced for Callio Therapeutics.
How can I track Callio Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Callio Therapeutics's shares on secondary markets.